SEVERE NEUROTOXICITY FOLLOWING HYPERFRACTIONATED ACCELERATED RADIOTHERAPY AND THIOTEPA IN THE TREATMENT OF HIGH-RISK MEDULLOBLASTOMA: THE UK EXPERIENCE

被引：0
|
作者：
Hayden, J. [1 ]
Vivekanandan, S. [2 ]
Thorp, N. [3 ]
Mayles, H. [4 ]
Baker, A. [4 ]
Pizer, B. [1 ]
Horan, G. [5 ]
机构：
[1] Alder Hey Childrens NHS Fdn Trust, Paediat Oncol, Liverpool, Merseyside, England
[2] Cambridge Univ Hosp NHS Fdn Trust, Paediat Oncol, Cambridge, England
[3] Clatterbridge Canc Ctr NHS Fdn Trust, Oncol, Wirral, Merseyside, England
[4] Clatterbridge Canc Ctr NHS Fdn Trust, Clin Radiotherapy, Wirral, Merseyside, England
[5] Cambridge Univ Hosp NHS Fdn Trust, Clin Oncol, Cambridge, England
来源：
PEDIATRIC BLOOD & CANCER | 2015年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
O-105
引用
收藏
页码：S172 / S173
页数：2
相关论文
共 50 条
  • [1] MRI abnormalities in children following sequential chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa for high-risk primitive neuroectodermal tumours of the central nervous system
    Thust, Stefanie C.
    Blanco, Esther
    Michalski, Antony J.
    Chong, W. K.
    Gaze, Mark N.
    Phipps, Kim
    Mankad, Kshitij
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2014, 58 (06) : 683 - 690
  • [2] METASTATIC MEDULLOBLASTOMA - UK RESULTS WITH INDUCTION AND HIGH DOSE CHEMOTHERAPY WITH HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (THE MILAN STRATEGY)
    Vivekanandan, S.
    Breene, R.
    Ramanujachar, R.
    Traunecker, H.
    Pizer, B.
    Gaze, M.
    Saran, F.
    Thorpe, N.
    Picton, S.
    English, M.
    Wheeler, K.
    Michalski, A.
    Walker, D. A.
    Saunders, D.
    Cowie, F.
    Cameron, A.
    Lee, V.
    Parashar, D. H.
    NEURO-ONCOLOGY, 2014, 16
  • [3] METASTATIC MEDULLOBLASTOMA - UK RESULTS WITH INDUCTION AND HIGH DOSE CHEMOTHERAPY WITH HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (THE MILAN STRATEGY)
    Vivekanandan, S.
    Breene, R.
    Ramanujachar, R.
    Traunecker, H.
    Pizer, B.
    Gaze, M.
    Saran, F.
    Thorp, N.
    English, M.
    Wheeler, K.
    Michalski, A.
    Walker, D. A.
    Saunders, D.
    Cowie, F.
    Cameron, A.
    Lee, V.
    Parashar, D.
    Horan, G.
    WIlliams, M.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S111 - S111
  • [4] Long-term outcome of the Milano-hyperfractionated accelerated radiotherapy strategy for high-risk medulloblastoma, including the impact of molecular subtype
    Massimino, Maura
    Barretta, Francesco
    Dossena, Chiara
    Minasi, Simone
    Buttarelli, Francesca Romana
    Biassoni, Veronica
    Oriani, Matilde
    Schiavello, Elisabetta
    Ficorilli, Marica
    Nigro, Olga
    Pollo, Bianca
    Antonelli, Manila
    Donofrio, Vittoria
    Maggioni, Marco
    Kool, Marcel
    Pecori, Emilia
    Vennarini, Sabina
    Giangaspero, Felice
    Gianno, Francesca
    Erbetta, Alessandra
    Chiapparini, Luisa
    Luksch, Roberto
    Barzano, Elena
    Meazza, Cristina
    Podda, Marta
    Spreafico, Filippo
    Terenziani, Monica
    Bergamaschi, Luca
    Ferrari, Andrea
    Casanova, Michela
    Chiaravalli, Stefano
    Gattuso, Giovanna
    Modena, Piergiorgio
    Bailey, Simon
    De Cecco, Loris
    NEURO-ONCOLOGY, 2024, 27 (01) : 209 - 218
  • [5] LONG TERM FOLLOW-UP OF PATIENTS WITH METASTATIC (M plus ) AND HIGH-RISK MEDULLOBLASTOMA WITH TAILORED-DOSES HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (HART) CSI PLUS/MINUS HIGH-DOSE THIOTEPA
    Massimino, M.
    Gandola, L.
    Spreafico, F.
    Biassoni, V.
    Schiavello, E.
    Pecori, E.
    Pignoli, E.
    Giandini, T.
    Luksch, R.
    Casanova, M.
    Ferrari, A.
    Terenziani, M.
    Poggi, G.
    Podda, M.
    Meazza, C.
    Catania, S.
    Chiaravalli, S.
    Puma, N.
    Boschetti, L.
    Veneroni, L.
    Antonelli, M.
    Buttarelli, F.
    Giangaspero, F.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S279 - S279
  • [6] MR IMAGING ABNORMALITIES FOLLOWING INDUCTION CHEMOTHERAPY, HYPERFRACTIONATED ACCELERATED RADIOTHERAPY AND HIGH DOSE THIOTEPA IN CHILDREN WITH PRIMITIVE NEUROECTODERMAL TUMOUR
    Thust, Stefanie
    Blanco, Esther
    Mankad, Kshitij
    Michalski, Antony
    NEURO-ONCOLOGY, 2014, 16 : 126 - 126
  • [7] Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for NSCLC: experience from nine UK centres
    Bradshaw, A. G.
    Esler, C.
    Roy, A. E. F.
    Toy, E.
    Lester, J. F.
    Kinsman, J.
    Atherton, P.
    Knox, C.
    Walker, G. A.
    Hatton, M. Q.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S24 - S25
  • [8] The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemotherapy (Milan Strategy)
    Vivekanandan, Sindu
    Breene, Richard
    Ramanujachar, Ramya
    Traunecker, Heidi
    Pizer, Barry
    Gaze, Mark N.
    Saran, Frank
    Thorp, Nicky
    English, Martin
    Wheeler, Kate A. H.
    Michalski, Antony
    Walker, David A.
    Saunders, Daniel
    Cowie, Fiona
    Cameron, Alison
    Picton, Susan V.
    Parashar, Deepak
    Horan, Gail
    Williams, Michael V.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (12) : 2132 - 2139
  • [9] A UK national review of radiotherapy treatment plans for paediatric medulloblastoma in cases of neurotoxicity
    Mayles, H.
    Baker, A.
    Thorp, N.
    Hayden, J.
    Horan, G.
    RADIOTHERAPY AND ONCOLOGY, 2015, 115 : S168 - S168
  • [10] LONG TERM FOLLOW-UP OF PATIENTS WITH METASTATIC (M1) AND OTHER HIGH-RISK MEDULLOBLASTOMA WITH TAILORED-DOSES HYPERFRACTIONATED ACCELERATED RADIOTHERAPY (HART) CRANIOSPINAL IRRADIATION (CSI) PLUS/MINUS HIGH-DOSE THIOTEPA
    Massimino, Maura
    Gandola, Lorenza
    Spreafico, Filippo
    Biassoni, Veronica
    Buttarelli, Francesca
    Schiavello, Elisabetta
    Pecori, Emilia
    Pignoli, Emanuele
    Giandini, Tommaso
    Luksch, Roberto
    Casanova, Michela
    Ferrari, Andrea
    Terenziani, Monica
    Poggi, Geraldina
    Podda, Marta
    Meazza, Cristina
    Catania, Serena
    Chiaravalli, Stefano
    Puma, Nadia
    Antonelli, Manila
    Giangaspero, Felice
    NEURO-ONCOLOGY, 2016, 18 : 97 - 97
12345